The long-term progression of macrodactyly

por Merel L.E. Stor, Max M. Lokhorst, Sophie E.R. Horbach, Chantal M.A.M. van der Horst
Publicado 2022

Gene polymorphisms in ULK1 and PIK3CA are associated with the risk of microscopic polyangiitis in the Guangxi Zhuang Autonomous Region in China

por Yan Zhu, Jinlan Rao, Jingsi Wei, Liu Liu, Shanshan Huang, Jingjing Lan, Chao Xue, Wei Li
Publicado 2021

Análisis molecular del cáncer de colon esporádico

por Hurtado,Claudia, Wielandt,Ana María, Zárate,Alejandro J, Kronberg,Udo, Castro,Magdalena, Yamagiwa,Ken, Ito,Takashi, Eishi,Yoshinobu, Contreras,Luis, López-Köstner,Francisco
Publicado 2015

The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia

por Tatiana N. Sokolova, Svetlana N. Aleksakhina, Grigoriy A. Yanus, Aleksandr V. Sultanbaev, Konstantin V. Menshikov, Anna N. Lysenko, Ruslan A. Zukov, Alena V. Zyuzyukina, Yulia N. Murunova, Elena I. Rossokha, Sergey Y. Bakharev, Elena A. Basova, Tatiana A. Kasmynina, Irina S. Shumskaya, Yana I. Bakshun, Khedi S. Musaeva, Alfia I. Khasanova, Vadim N. Dmitriev, Marina B. Bolieva, Christina H. Gadzaova, Oleg L. Petrenko, Dmitriy A. Maksimov, Vladimir I. Vladimirov, Viktor E. Goldberg, Nataliya O. Popova, Marianna V. Kibisheva, Zaur M. Khamgokov, Alexey E. Vasilyev, Aglaya G. Iyevleva, Evgeny N. Imyanitov
Publicado 2021

Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data

por Armaghani AJ, Han HS
Publicado 2020

Data provision of PIK3CA gene diversity and recombinant plasmids preparation for control DNA in developing the trastuzumab predictive response diagnostic kit

por DESRIANI DESRIANI, BUGI RATNO BUDIARTO, WIRSMA ARIF HARAHAP, M. ALI WARISMAN, AUDREY VANIA CLARISSA OMPUSUNGGU, DINA ATHARIAH, FARIDA MIRNAWATI, IDA YUSSRIYANI, FUAD ALAHWANI, AHMAD RIZQI KURNIAWAN
Publicado 2016

The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib

por Natalya V. Mazurina, Elena V. Artamonova, Maria F. Beloyartseva, Ekaterina I. Volkova, Inna P. Ganshina, Ekaterina A. Troshina, Sergey A. Tjulandin, Viacheslav A. Chubenko
Publicado 2021

The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review

por Irina V. Poddubnaya, Joseph Gligorov, Liudmila G. Zhukova, Elena I. Kovalenko, M. A. Frolova
Publicado 2021

Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 2...

por Editorial Board
Publicado 2021

PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum ded...

por Editorial Board
Publicado 2021

Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives

por Chang DY, Ma WL, Lu YS
Publicado 2021